ImmunoGen (NASDAQ:IMGN) is up 21.8% at 1:06 p.m. EST on no apparent news. Of course, it’s a biotech, so that’s often par for the course.
One possibility is that day traders are just doing their thing, following the momentum, which pushes the stock price higher. We’ll know in a few days if the share price returns to previous levels.
Image source: Getty Images.
It’s also possible investors are buying ahead of the Society of Gynecologic Oncology’s Annual Meeting of Women’s Cancer next month where ImmunoGen is scheduled to present additional phase 1 data from a subset of patients getting its cancer medication mirvetuximab soravtansine.
The clinical trial tests mirvetuximab soravtansine in relapsed epithelial ovarian cancer patients. In this cohort, the patients got a fresh biopsy to measure expression levels of FR alpha, which mirvetuximab soravtansine targets. The hope is that expression levels will continue to align with patient outcomes — that is, patients with more FR alpha respond better — and that the fresh biopsy will show the same results as the archival biopsy.
Mirvetuximab soravtansine is already being tested in a phase 3 clinical trial called FORWARD I, which uses archived biopsies to select patients. Assuming the fresh biopsies match with the archival biopsy samples, investors can rest assured that ImmunoGen’s patient selection strategy for FORWARD I is sound.
Unlike many medical meetings that release abstracts before the meeting, giving investors a peek at preliminary data, the Society of Gynecologic Oncology waits until the start of the session during which they are presented. Investors will have to wait until March 13 or 14, depending on which poster session the presentation is assigned, to see the full data set.
Until then, investors should make sure they have stomachs for a potentially bumpy ride.